nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—SRC—colon cancer	0.375	0.83	CbGaD
Dasatinib—ABCB1—colon cancer	0.0766	0.17	CbGaD
Dasatinib—ABCG2—Irinotecan—colon cancer	0.0208	0.165	CbGbCtD
Dasatinib—ABCG2—Fluorouracil—colon cancer	0.02	0.158	CbGbCtD
Dasatinib—ABCG2—Vincristine—colon cancer	0.0182	0.144	CbGbCtD
Dasatinib—CYP3A5—Irinotecan—colon cancer	0.0115	0.0913	CbGbCtD
Dasatinib—ABCG2—Methotrexate—colon cancer	0.011	0.0872	CbGbCtD
Dasatinib—CYP3A5—Vincristine—colon cancer	0.0101	0.0798	CbGbCtD
Dasatinib—CYP1A2—Fluorouracil—colon cancer	0.00825	0.0652	CbGbCtD
Dasatinib—ABCB1—Irinotecan—colon cancer	0.00751	0.0594	CbGbCtD
Dasatinib—ABCB1—Vincristine—colon cancer	0.00657	0.0519	CbGbCtD
Dasatinib—CYP3A4—Irinotecan—colon cancer	0.0045	0.0356	CbGbCtD
Dasatinib—ABCB1—Methotrexate—colon cancer	0.00398	0.0314	CbGbCtD
Dasatinib—CYP3A4—Vincristine—colon cancer	0.00393	0.0311	CbGbCtD
Dasatinib—ABL1—Topotecan—Irinotecan—colon cancer	0.00179	0.675	CbGdCrCtD
Dasatinib—ERBB3—Vinblastine—Vincristine—colon cancer	0.000863	0.325	CbGdCrCtD
Dasatinib—FRK—liver—colon cancer	0.000533	0.00454	CbGeAlD
Dasatinib—CSK—smooth muscle tissue—colon cancer	0.000531	0.00452	CbGeAlD
Dasatinib—JAK2—embryo—colon cancer	0.000526	0.00447	CbGeAlD
Dasatinib—ZAK—lymphoid tissue—colon cancer	0.000524	0.00446	CbGeAlD
Dasatinib—FYN—embryo—colon cancer	0.000519	0.00441	CbGeAlD
Dasatinib—ZAK—digestive system—colon cancer	0.000518	0.0044	CbGeAlD
Dasatinib—RIPK2—epithelium—colon cancer	0.000511	0.00435	CbGeAlD
Dasatinib—CSK—renal system—colon cancer	0.000511	0.00435	CbGeAlD
Dasatinib—LYN—lymphoid tissue—colon cancer	0.00051	0.00434	CbGeAlD
Dasatinib—EPHA5—digestive system—colon cancer	0.000507	0.00431	CbGeAlD
Dasatinib—BTK—lymphoid tissue—colon cancer	0.0005	0.00425	CbGeAlD
Dasatinib—ERBB3—epithelium—colon cancer	0.000489	0.00416	CbGeAlD
Dasatinib—EPHB1—lymph node—colon cancer	0.000475	0.00404	CbGeAlD
Dasatinib—SIK1—renal system—colon cancer	0.000463	0.00394	CbGeAlD
Dasatinib—STAT5B—liver—colon cancer	0.000461	0.00392	CbGeAlD
Dasatinib—PDGFRA—embryo—colon cancer	0.000459	0.00391	CbGeAlD
Dasatinib—ZAK—vagina—colon cancer	0.000457	0.00389	CbGeAlD
Dasatinib—MAPK14—epithelium—colon cancer	0.000456	0.00388	CbGeAlD
Dasatinib—BTK—bone marrow—colon cancer	0.000455	0.00387	CbGeAlD
Dasatinib—ERBB3—renal system—colon cancer	0.000454	0.00386	CbGeAlD
Dasatinib—EPHB3—digestive system—colon cancer	0.00045	0.00383	CbGeAlD
Dasatinib—SRC—embryo—colon cancer	0.00045	0.00383	CbGeAlD
Dasatinib—EPHA5—vagina—colon cancer	0.000447	0.00381	CbGeAlD
Dasatinib—LIMK2—lymphoid tissue—colon cancer	0.000441	0.00375	CbGeAlD
Dasatinib—MAPK14—smooth muscle tissue—colon cancer	0.000439	0.00374	CbGeAlD
Dasatinib—BTK—vagina—colon cancer	0.000436	0.00371	CbGeAlD
Dasatinib—EPHB4—epithelium—colon cancer	0.000432	0.00368	CbGeAlD
Dasatinib—JAK2—epithelium—colon cancer	0.000429	0.00365	CbGeAlD
Dasatinib—CSK—lymphoid tissue—colon cancer	0.000424	0.00361	CbGeAlD
Dasatinib—EPHA2—epithelium—colon cancer	0.000424	0.00361	CbGeAlD
Dasatinib—MAPK14—renal system—colon cancer	0.000423	0.0036	CbGeAlD
Dasatinib—CSK—digestive system—colon cancer	0.000419	0.00357	CbGeAlD
Dasatinib—HCK—lymphoid tissue—colon cancer	0.000419	0.00356	CbGeAlD
Dasatinib—EPHB4—smooth muscle tissue—colon cancer	0.000416	0.00354	CbGeAlD
Dasatinib—SIK3—liver—colon cancer	0.000415	0.00353	CbGeAlD
Dasatinib—HCK—digestive system—colon cancer	0.000414	0.00352	CbGeAlD
Dasatinib—JAK2—smooth muscle tissue—colon cancer	0.000413	0.00352	CbGeAlD
Dasatinib—FYN—smooth muscle tissue—colon cancer	0.000408	0.00347	CbGeAlD
Dasatinib—CSF1R—embryo—colon cancer	0.000404	0.00344	CbGeAlD
Dasatinib—TESK1—vagina—colon cancer	0.000404	0.00344	CbGeAlD
Dasatinib—EPHB4—renal system—colon cancer	0.000401	0.00341	CbGeAlD
Dasatinib—BMX—lymph node—colon cancer	0.000399	0.0034	CbGeAlD
Dasatinib—MAP4K5—smooth muscle tissue—colon cancer	0.000398	0.00339	CbGeAlD
Dasatinib—JAK2—renal system—colon cancer	0.000398	0.00339	CbGeAlD
Dasatinib—EPHB3—vagina—colon cancer	0.000398	0.00338	CbGeAlD
Dasatinib—STK36—vagina—colon cancer	0.000398	0.00338	CbGeAlD
Dasatinib—BLK—lymph node—colon cancer	0.000395	0.00336	CbGeAlD
Dasatinib—FYN—renal system—colon cancer	0.000393	0.00334	CbGeAlD
Dasatinib—RIPK2—digestive system—colon cancer	0.000389	0.00331	CbGeAlD
Dasatinib—CSK—bone marrow—colon cancer	0.000386	0.00329	CbGeAlD
Dasatinib—ZAK—liver—colon cancer	0.000386	0.00328	CbGeAlD
Dasatinib—SIK1—lymphoid tissue—colon cancer	0.000385	0.00327	CbGeAlD
Dasatinib—LIMK2—vagina—colon cancer	0.000384	0.00327	CbGeAlD
Dasatinib—HCK—bone marrow—colon cancer	0.000381	0.00324	CbGeAlD
Dasatinib—TXK—lymph node—colon cancer	0.000378	0.00321	CbGeAlD
Dasatinib—ERBB3—lymphoid tissue—colon cancer	0.000377	0.00321	CbGeAlD
Dasatinib—LYN—liver—colon cancer	0.000375	0.00319	CbGeAlD
Dasatinib—MAP3K2—lymphoid tissue—colon cancer	0.000373	0.00318	CbGeAlD
Dasatinib—STK35—vagina—colon cancer	0.000373	0.00317	CbGeAlD
Dasatinib—ERBB3—digestive system—colon cancer	0.000372	0.00317	CbGeAlD
Dasatinib—CSK—vagina—colon cancer	0.00037	0.00315	CbGeAlD
Dasatinib—YES1—smooth muscle tissue—colon cancer	0.000368	0.00313	CbGeAlD
Dasatinib—BTK—liver—colon cancer	0.000368	0.00313	CbGeAlD
Dasatinib—SRC—epithelium—colon cancer	0.000367	0.00313	CbGeAlD
Dasatinib—KIT—embryo—colon cancer	0.000367	0.00312	CbGeAlD
Dasatinib—HCK—vagina—colon cancer	0.000365	0.00311	CbGeAlD
Dasatinib—ABL2—vagina—colon cancer	0.000363	0.00309	CbGeAlD
Dasatinib—TNK2—liver—colon cancer	0.000363	0.00308	CbGeAlD
Dasatinib—PDGFRA—smooth muscle tissue—colon cancer	0.000361	0.00307	CbGeAlD
Dasatinib—RIPK2—bone marrow—colon cancer	0.000359	0.00305	CbGeAlD
Dasatinib—PDGFRB—embryo—colon cancer	0.000358	0.00305	CbGeAlD
Dasatinib—YES1—renal system—colon cancer	0.000354	0.00301	CbGeAlD
Dasatinib—SRC—smooth muscle tissue—colon cancer	0.000354	0.00301	CbGeAlD
Dasatinib—STAT5B—lymph node—colon cancer	0.000354	0.00301	CbGeAlD
Dasatinib—MAPK14—lymphoid tissue—colon cancer	0.000351	0.00299	CbGeAlD
Dasatinib—SIK1—bone marrow—colon cancer	0.00035	0.00298	CbGeAlD
Dasatinib—FGR—lymphoid tissue—colon cancer	0.00035	0.00297	CbGeAlD
Dasatinib—PDGFRA—renal system—colon cancer	0.000347	0.00296	CbGeAlD
Dasatinib—MAPK14—digestive system—colon cancer	0.000347	0.00295	CbGeAlD
Dasatinib—FGR—digestive system—colon cancer	0.000345	0.00294	CbGeAlD
Dasatinib—RIPK2—vagina—colon cancer	0.000344	0.00292	CbGeAlD
Dasatinib—TESK1—liver—colon cancer	0.000341	0.0029	CbGeAlD
Dasatinib—SRC—renal system—colon cancer	0.000341	0.0029	CbGeAlD
Dasatinib—MAP3K2—bone marrow—colon cancer	0.00034	0.00289	CbGeAlD
Dasatinib—STK36—liver—colon cancer	0.000335	0.00285	CbGeAlD
Dasatinib—EPHA4—vagina—colon cancer	0.000332	0.00283	CbGeAlD
Dasatinib—JAK2—lymphoid tissue—colon cancer	0.00033	0.00281	CbGeAlD
Dasatinib—EPHB4—digestive system—colon cancer	0.000329	0.0028	CbGeAlD
Dasatinib—EPHA3—lymph node—colon cancer	0.000327	0.00278	CbGeAlD
Dasatinib—EPHA2—lymphoid tissue—colon cancer	0.000326	0.00278	CbGeAlD
Dasatinib—JAK2—digestive system—colon cancer	0.000326	0.00278	CbGeAlD
Dasatinib—FYN—lymphoid tissue—colon cancer	0.000326	0.00277	CbGeAlD
Dasatinib—LIMK2—liver—colon cancer	0.000324	0.00276	CbGeAlD
Dasatinib—EPHA2—digestive system—colon cancer	0.000322	0.00274	CbGeAlD
Dasatinib—FYN—digestive system—colon cancer	0.000322	0.00274	CbGeAlD
Dasatinib—MAPK14—bone marrow—colon cancer	0.00032	0.00272	CbGeAlD
Dasatinib—ABL1—embryo—colon cancer	0.00032	0.00272	CbGeAlD
Dasatinib—MAP4K5—lymphoid tissue—colon cancer	0.000318	0.00271	CbGeAlD
Dasatinib—FGR—bone marrow—colon cancer	0.000318	0.00271	CbGeAlD
Dasatinib—LCK—bone marrow—colon cancer	0.000318	0.00271	CbGeAlD
Dasatinib—SIK3—lymph node—colon cancer	0.000318	0.00271	CbGeAlD
Dasatinib—CSF1R—smooth muscle tissue—colon cancer	0.000318	0.0027	CbGeAlD
Dasatinib—STK35—liver—colon cancer	0.000314	0.00267	CbGeAlD
Dasatinib—CSK—liver—colon cancer	0.000312	0.00266	CbGeAlD
Dasatinib—HCK—liver—colon cancer	0.000308	0.00262	CbGeAlD
Dasatinib—ABL2—liver—colon cancer	0.000306	0.00261	CbGeAlD
Dasatinib—MAPK14—vagina—colon cancer	0.000306	0.0026	CbGeAlD
Dasatinib—FGR—vagina—colon cancer	0.000305	0.00259	CbGeAlD
Dasatinib—LCK—vagina—colon cancer	0.000305	0.00259	CbGeAlD
Dasatinib—EPHB4—bone marrow—colon cancer	0.000303	0.00258	CbGeAlD
Dasatinib—JAK2—bone marrow—colon cancer	0.000301	0.00256	CbGeAlD
Dasatinib—KIT—epithelium—colon cancer	0.0003	0.00255	CbGeAlD
Dasatinib—FYN—bone marrow—colon cancer	0.000297	0.00252	CbGeAlD
Dasatinib—ZAK—lymph node—colon cancer	0.000296	0.00251	CbGeAlD
Dasatinib—FMO3—vagina—colon cancer	0.000295	0.00251	CbGeAlD
Dasatinib—YES1—lymphoid tissue—colon cancer	0.000294	0.0025	CbGeAlD
Dasatinib—PDGFRB—epithelium—colon cancer	0.000293	0.00249	CbGeAlD
Dasatinib—YES1—digestive system—colon cancer	0.000291	0.00247	CbGeAlD
Dasatinib—EPHB4—vagina—colon cancer	0.00029	0.00247	CbGeAlD
Dasatinib—MAP3K3—bone marrow—colon cancer	0.00029	0.00247	CbGeAlD
Dasatinib—MAP4K5—bone marrow—colon cancer	0.00029	0.00247	CbGeAlD
Dasatinib—RIPK2—liver—colon cancer	0.00029	0.00247	CbGeAlD
Dasatinib—KIT—smooth muscle tissue—colon cancer	0.000289	0.00245	CbGeAlD
Dasatinib—PDGFRA—lymphoid tissue—colon cancer	0.000289	0.00245	CbGeAlD
Dasatinib—JAK2—vagina—colon cancer	0.000288	0.00245	CbGeAlD
Dasatinib—PDGFRA—digestive system—colon cancer	0.000285	0.00242	CbGeAlD
Dasatinib—EPHA2—vagina—colon cancer	0.000285	0.00242	CbGeAlD
Dasatinib—FYN—vagina—colon cancer	0.000284	0.00242	CbGeAlD
Dasatinib—BMPR1B—lymph node—colon cancer	0.000283	0.00241	CbGeAlD
Dasatinib—SIK1—liver—colon cancer	0.000283	0.00241	CbGeAlD
Dasatinib—SRC—lymphoid tissue—colon cancer	0.000283	0.00241	CbGeAlD
Dasatinib—BTK—lymph node—colon cancer	0.000282	0.0024	CbGeAlD
Dasatinib—PDGFRB—smooth muscle tissue—colon cancer	0.000282	0.0024	CbGeAlD
Dasatinib—SRC—digestive system—colon cancer	0.00028	0.00238	CbGeAlD
Dasatinib—TNK2—lymph node—colon cancer	0.000278	0.00236	CbGeAlD
Dasatinib—MAP4K5—vagina—colon cancer	0.000278	0.00236	CbGeAlD
Dasatinib—MAP3K3—vagina—colon cancer	0.000278	0.00236	CbGeAlD
Dasatinib—KIT—renal system—colon cancer	0.000278	0.00236	CbGeAlD
Dasatinib—ERBB3—liver—colon cancer	0.000277	0.00236	CbGeAlD
Dasatinib—MAP3K2—liver—colon cancer	0.000275	0.00234	CbGeAlD
Dasatinib—PDGFRB—renal system—colon cancer	0.000271	0.00231	CbGeAlD
Dasatinib—YES1—bone marrow—colon cancer	0.000268	0.00228	CbGeAlD
Dasatinib—EPHB6—vagina—colon cancer	0.000266	0.00226	CbGeAlD
Dasatinib—TESK1—lymph node—colon cancer	0.000261	0.00222	CbGeAlD
Dasatinib—MAPK14—liver—colon cancer	0.000258	0.0022	CbGeAlD
Dasatinib—FGR—liver—colon cancer	0.000257	0.00219	CbGeAlD
Dasatinib—LCK—liver—colon cancer	0.000257	0.00219	CbGeAlD
Dasatinib—STK36—lymph node—colon cancer	0.000257	0.00219	CbGeAlD
Dasatinib—EPHB3—lymph node—colon cancer	0.000257	0.00219	CbGeAlD
Dasatinib—YES1—vagina—colon cancer	0.000257	0.00218	CbGeAlD
Dasatinib—CSF1R—lymphoid tissue—colon cancer	0.000254	0.00216	CbGeAlD
Dasatinib—PDGFRA—vagina—colon cancer	0.000252	0.00214	CbGeAlD
Dasatinib—ABL1—smooth muscle tissue—colon cancer	0.000251	0.00214	CbGeAlD
Dasatinib—CSF1R—digestive system—colon cancer	0.000251	0.00213	CbGeAlD
Dasatinib—LIMK2—lymph node—colon cancer	0.000249	0.00212	CbGeAlD
Dasatinib—FMO3—liver—colon cancer	0.000248	0.00211	CbGeAlD
Dasatinib—EPHB4—liver—colon cancer	0.000245	0.00208	CbGeAlD
Dasatinib—JAK2—liver—colon cancer	0.000243	0.00207	CbGeAlD
Dasatinib—ABL1—renal system—colon cancer	0.000242	0.00206	CbGeAlD
Dasatinib—STK35—lymph node—colon cancer	0.000241	0.00205	CbGeAlD
Dasatinib—EPHA2—liver—colon cancer	0.00024	0.00204	CbGeAlD
Dasatinib—FYN—liver—colon cancer	0.00024	0.00204	CbGeAlD
Dasatinib—CSK—lymph node—colon cancer	0.000239	0.00204	CbGeAlD
Dasatinib—HCK—lymph node—colon cancer	0.000236	0.00201	CbGeAlD
Dasatinib—ABL2—lymph node—colon cancer	0.000235	0.002	CbGeAlD
Dasatinib—MAP4K5—liver—colon cancer	0.000234	0.00199	CbGeAlD
Dasatinib—MAP3K3—liver—colon cancer	0.000234	0.00199	CbGeAlD
Dasatinib—CSF1R—bone marrow—colon cancer	0.000231	0.00197	CbGeAlD
Dasatinib—KIT—lymphoid tissue—colon cancer	0.000231	0.00196	CbGeAlD
Dasatinib—KIT—digestive system—colon cancer	0.000228	0.00194	CbGeAlD
Dasatinib—MAP2K5—vagina—colon cancer	0.000227	0.00193	CbGeAlD
Dasatinib—PDGFRB—lymphoid tissue—colon cancer	0.000225	0.00192	CbGeAlD
Dasatinib—PDGFRB—digestive system—colon cancer	0.000223	0.00189	CbGeAlD
Dasatinib—RIPK2—lymph node—colon cancer	0.000222	0.00189	CbGeAlD
Dasatinib—CSF1R—vagina—colon cancer	0.000222	0.00188	CbGeAlD
Dasatinib—SIK1—lymph node—colon cancer	0.000217	0.00185	CbGeAlD
Dasatinib—YES1—liver—colon cancer	0.000216	0.00184	CbGeAlD
Dasatinib—EPHA4—lymph node—colon cancer	0.000215	0.00183	CbGeAlD
Dasatinib—CYP1B1—smooth muscle tissue—colon cancer	0.000213	0.00181	CbGeAlD
Dasatinib—ERBB3—lymph node—colon cancer	0.000213	0.00181	CbGeAlD
Dasatinib—PDGFRA—liver—colon cancer	0.000212	0.00181	CbGeAlD
Dasatinib—MAP3K2—lymph node—colon cancer	0.000211	0.00179	CbGeAlD
Dasatinib—KIT—bone marrow—colon cancer	0.00021	0.00179	CbGeAlD
Dasatinib—SRC—liver—colon cancer	0.000208	0.00177	CbGeAlD
Dasatinib—PDGFRB—bone marrow—colon cancer	0.000205	0.00175	CbGeAlD
Dasatinib—CYP1B1—renal system—colon cancer	0.000205	0.00174	CbGeAlD
Dasatinib—KIT—vagina—colon cancer	0.000201	0.00171	CbGeAlD
Dasatinib—ABL1—lymphoid tissue—colon cancer	0.000201	0.00171	CbGeAlD
Dasatinib—ABL1—digestive system—colon cancer	0.000198	0.00169	CbGeAlD
Dasatinib—MAPK14—lymph node—colon cancer	0.000198	0.00168	CbGeAlD
Dasatinib—FGR—lymph node—colon cancer	0.000197	0.00168	CbGeAlD
Dasatinib—LCK—lymph node—colon cancer	0.000197	0.00168	CbGeAlD
Dasatinib—PDGFRB—vagina—colon cancer	0.000197	0.00167	CbGeAlD
Dasatinib—MAP2K5—liver—colon cancer	0.000192	0.00163	CbGeAlD
Dasatinib—FMO3—lymph node—colon cancer	0.000191	0.00162	CbGeAlD
Dasatinib—EPHB4—lymph node—colon cancer	0.000188	0.0016	CbGeAlD
Dasatinib—CSF1R—liver—colon cancer	0.000187	0.00159	CbGeAlD
Dasatinib—JAK2—lymph node—colon cancer	0.000186	0.00159	CbGeAlD
Dasatinib—EPHA2—lymph node—colon cancer	0.000184	0.00157	CbGeAlD
Dasatinib—FYN—lymph node—colon cancer	0.000184	0.00156	CbGeAlD
Dasatinib—ABL1—bone marrow—colon cancer	0.000183	0.00156	CbGeAlD
Dasatinib—MAP4K5—lymph node—colon cancer	0.00018	0.00153	CbGeAlD
Dasatinib—MAP3K3—lymph node—colon cancer	0.00018	0.00153	CbGeAlD
Dasatinib—ABL1—vagina—colon cancer	0.000175	0.00149	CbGeAlD
Dasatinib—EPHB6—lymph node—colon cancer	0.000172	0.00146	CbGeAlD
Dasatinib—CYP1B1—lymphoid tissue—colon cancer	0.00017	0.00145	CbGeAlD
Dasatinib—KIT—liver—colon cancer	0.00017	0.00144	CbGeAlD
Dasatinib—CYP1B1—digestive system—colon cancer	0.000168	0.00143	CbGeAlD
Dasatinib—ABCB1—blood vessel—colon cancer	0.000167	0.00142	CbGeAlD
Dasatinib—YES1—lymph node—colon cancer	0.000166	0.00141	CbGeAlD
Dasatinib—PDGFRB—liver—colon cancer	0.000166	0.00141	CbGeAlD
Dasatinib—PDGFRA—lymph node—colon cancer	0.000163	0.00138	CbGeAlD
Dasatinib—SRC—lymph node—colon cancer	0.00016	0.00136	CbGeAlD
Dasatinib—Myocardial infarction—Capecitabine—colon cancer	0.000157	0.00132	CcSEcCtD
Dasatinib—Oedema—Vincristine—colon cancer	0.000156	0.00132	CcSEcCtD
Dasatinib—CYP1A1—epithelium—colon cancer	0.000156	0.00133	CbGeAlD
Dasatinib—Stomatitis—Capecitabine—colon cancer	0.000156	0.00132	CcSEcCtD
Dasatinib—Infection—Vincristine—colon cancer	0.000155	0.00131	CcSEcCtD
Dasatinib—Conjunctivitis—Capecitabine—colon cancer	0.000155	0.00131	CcSEcCtD
Dasatinib—Convulsion—Fluorouracil—colon cancer	0.000155	0.00131	CcSEcCtD
Dasatinib—Confusional state—Irinotecan—colon cancer	0.000154	0.0013	CcSEcCtD
Dasatinib—Nervous system disorder—Vincristine—colon cancer	0.000153	0.0013	CcSEcCtD
Dasatinib—Thrombocytopenia—Vincristine—colon cancer	0.000153	0.00129	CcSEcCtD
Dasatinib—Haematuria—Capecitabine—colon cancer	0.000152	0.00129	CcSEcCtD
Dasatinib—Oedema—Irinotecan—colon cancer	0.000152	0.00129	CcSEcCtD
Dasatinib—Chest pain—Fluorouracil—colon cancer	0.000152	0.00129	CcSEcCtD
Dasatinib—Myalgia—Fluorouracil—colon cancer	0.000152	0.00129	CcSEcCtD
Dasatinib—Infection—Irinotecan—colon cancer	0.000151	0.00128	CcSEcCtD
Dasatinib—Hyperhidrosis—Vincristine—colon cancer	0.000151	0.00128	CcSEcCtD
Dasatinib—Hepatobiliary disease—Capecitabine—colon cancer	0.000151	0.00128	CcSEcCtD
Dasatinib—Epistaxis—Capecitabine—colon cancer	0.000151	0.00127	CcSEcCtD
Dasatinib—Discomfort—Fluorouracil—colon cancer	0.00015	0.00127	CcSEcCtD
Dasatinib—Shock—Irinotecan—colon cancer	0.00015	0.00127	CcSEcCtD
Dasatinib—Nervous system disorder—Irinotecan—colon cancer	0.000149	0.00126	CcSEcCtD
Dasatinib—Thrombocytopenia—Irinotecan—colon cancer	0.000149	0.00126	CcSEcCtD
Dasatinib—Anorexia—Vincristine—colon cancer	0.000149	0.00126	CcSEcCtD
Dasatinib—ABL1—liver—colon cancer	0.000148	0.00126	CbGeAlD
Dasatinib—Hyperhidrosis—Irinotecan—colon cancer	0.000147	0.00124	CcSEcCtD
Dasatinib—Confusional state—Fluorouracil—colon cancer	0.000147	0.00124	CcSEcCtD
Dasatinib—MAP2K5—lymph node—colon cancer	0.000147	0.00125	CbGeAlD
Dasatinib—CYP1A2—renal system—colon cancer	0.000147	0.00125	CbGeAlD
Dasatinib—Hypotension—Vincristine—colon cancer	0.000146	0.00123	CcSEcCtD
Dasatinib—Oedema—Fluorouracil—colon cancer	0.000146	0.00123	CcSEcCtD
Dasatinib—Anorexia—Irinotecan—colon cancer	0.000145	0.00123	CcSEcCtD
Dasatinib—Infection—Fluorouracil—colon cancer	0.000145	0.00122	CcSEcCtD
Dasatinib—CYP1A1—renal system—colon cancer	0.000145	0.00123	CbGeAlD
Dasatinib—Haemoglobin—Capecitabine—colon cancer	0.000144	0.00122	CcSEcCtD
Dasatinib—Hepatitis—Capecitabine—colon cancer	0.000143	0.00121	CcSEcCtD
Dasatinib—Haemorrhage—Capecitabine—colon cancer	0.000143	0.00121	CcSEcCtD
Dasatinib—CSF1R—lymph node—colon cancer	0.000143	0.00122	CbGeAlD
Dasatinib—Nervous system disorder—Fluorouracil—colon cancer	0.000143	0.00121	CcSEcCtD
Dasatinib—Thrombocytopenia—Fluorouracil—colon cancer	0.000143	0.00121	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Vincristine—colon cancer	0.000142	0.0012	CcSEcCtD
Dasatinib—Tachycardia—Fluorouracil—colon cancer	0.000142	0.0012	CcSEcCtD
Dasatinib—Hypotension—Irinotecan—colon cancer	0.000142	0.0012	CcSEcCtD
Dasatinib—Urinary tract disorder—Capecitabine—colon cancer	0.000142	0.0012	CcSEcCtD
Dasatinib—CYP3A5—renal system—colon cancer	0.000142	0.0012	CbGeAlD
Dasatinib—Insomnia—Vincristine—colon cancer	0.000141	0.0012	CcSEcCtD
Dasatinib—Oedema peripheral—Capecitabine—colon cancer	0.000141	0.00119	CcSEcCtD
Dasatinib—Connective tissue disorder—Capecitabine—colon cancer	0.000141	0.00119	CcSEcCtD
Dasatinib—Urethral disorder—Capecitabine—colon cancer	0.000141	0.00119	CcSEcCtD
Dasatinib—Breast disorder—Methotrexate—colon cancer	0.000139	0.00118	CcSEcCtD
Dasatinib—Anorexia—Fluorouracil—colon cancer	0.000139	0.00117	CcSEcCtD
Dasatinib—Visual impairment—Capecitabine—colon cancer	0.000138	0.00117	CcSEcCtD
Dasatinib—Insomnia—Irinotecan—colon cancer	0.000138	0.00116	CcSEcCtD
Dasatinib—Hypotension—Fluorouracil—colon cancer	0.000136	0.00115	CcSEcCtD
Dasatinib—Decreased appetite—Vincristine—colon cancer	0.000136	0.00115	CcSEcCtD
Dasatinib—Dyspnoea—Irinotecan—colon cancer	0.000136	0.00115	CcSEcCtD
Dasatinib—Erythema multiforme—Capecitabine—colon cancer	0.000136	0.00115	CcSEcCtD
Dasatinib—Somnolence—Irinotecan—colon cancer	0.000135	0.00114	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Vincristine—colon cancer	0.000135	0.00114	CcSEcCtD
Dasatinib—Fatigue—Vincristine—colon cancer	0.000135	0.00114	CcSEcCtD
Dasatinib—Eye disorder—Capecitabine—colon cancer	0.000134	0.00113	CcSEcCtD
Dasatinib—Dyspepsia—Irinotecan—colon cancer	0.000134	0.00113	CcSEcCtD
Dasatinib—Tinnitus—Capecitabine—colon cancer	0.000134	0.00113	CcSEcCtD
Dasatinib—Constipation—Vincristine—colon cancer	0.000134	0.00113	CcSEcCtD
Dasatinib—Pain—Vincristine—colon cancer	0.000134	0.00113	CcSEcCtD
Dasatinib—Asthma—Methotrexate—colon cancer	0.000133	0.00113	CcSEcCtD
Dasatinib—Flushing—Capecitabine—colon cancer	0.000133	0.00112	CcSEcCtD
Dasatinib—Cardiac disorder—Capecitabine—colon cancer	0.000133	0.00112	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000133	0.00112	CcSEcCtD
Dasatinib—Decreased appetite—Irinotecan—colon cancer	0.000132	0.00112	CcSEcCtD
Dasatinib—Insomnia—Fluorouracil—colon cancer	0.000132	0.00111	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Irinotecan—colon cancer	0.000131	0.00111	CcSEcCtD
Dasatinib—Fatigue—Irinotecan—colon cancer	0.000131	0.00111	CcSEcCtD
Dasatinib—Pancreatitis—Methotrexate—colon cancer	0.000131	0.00111	CcSEcCtD
Dasatinib—Constipation—Irinotecan—colon cancer	0.00013	0.0011	CcSEcCtD
Dasatinib—Pain—Irinotecan—colon cancer	0.00013	0.0011	CcSEcCtD
Dasatinib—KIT—lymph node—colon cancer	0.00013	0.00111	CbGeAlD
Dasatinib—Angiopathy—Capecitabine—colon cancer	0.00013	0.0011	CcSEcCtD
Dasatinib—Dyspnoea—Fluorouracil—colon cancer	0.00013	0.0011	CcSEcCtD
Dasatinib—Somnolence—Fluorouracil—colon cancer	0.00013	0.0011	CcSEcCtD
Dasatinib—Immune system disorder—Capecitabine—colon cancer	0.00013	0.00109	CcSEcCtD
Dasatinib—Mediastinal disorder—Capecitabine—colon cancer	0.000129	0.00109	CcSEcCtD
Dasatinib—Chills—Capecitabine—colon cancer	0.000129	0.00109	CcSEcCtD
Dasatinib—Dyspepsia—Fluorouracil—colon cancer	0.000128	0.00108	CcSEcCtD
Dasatinib—Arrhythmia—Capecitabine—colon cancer	0.000128	0.00108	CcSEcCtD
Dasatinib—Gastrointestinal pain—Vincristine—colon cancer	0.000128	0.00108	CcSEcCtD
Dasatinib—PDGFRB—lymph node—colon cancer	0.000127	0.00108	CbGeAlD
Dasatinib—Decreased appetite—Fluorouracil—colon cancer	0.000127	0.00107	CcSEcCtD
Dasatinib—Alopecia—Capecitabine—colon cancer	0.000127	0.00107	CcSEcCtD
Dasatinib—Pancytopenia—Methotrexate—colon cancer	0.000127	0.00107	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000126	0.00106	CcSEcCtD
Dasatinib—Mental disorder—Capecitabine—colon cancer	0.000126	0.00106	CcSEcCtD
Dasatinib—Feeling abnormal—Irinotecan—colon cancer	0.000125	0.00106	CcSEcCtD
Dasatinib—CYP1B1—liver—colon cancer	0.000125	0.00106	CbGeAlD
Dasatinib—Malnutrition—Capecitabine—colon cancer	0.000125	0.00106	CcSEcCtD
Dasatinib—Erythema—Capecitabine—colon cancer	0.000125	0.00106	CcSEcCtD
Dasatinib—Neutropenia—Methotrexate—colon cancer	0.000125	0.00105	CcSEcCtD
Dasatinib—Pain—Fluorouracil—colon cancer	0.000125	0.00105	CcSEcCtD
Dasatinib—Gastrointestinal pain—Irinotecan—colon cancer	0.000124	0.00105	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Methotrexate—colon cancer	0.000124	0.00105	CcSEcCtD
Dasatinib—Body temperature increased—Vincristine—colon cancer	0.000124	0.00104	CcSEcCtD
Dasatinib—Abdominal pain—Vincristine—colon cancer	0.000124	0.00104	CcSEcCtD
Dasatinib—Dysgeusia—Capecitabine—colon cancer	0.000122	0.00103	CcSEcCtD
Dasatinib—Photosensitivity reaction—Methotrexate—colon cancer	0.000122	0.00103	CcSEcCtD
Dasatinib—CYP1A2—digestive system—colon cancer	0.00012	0.00102	CbGeAlD
Dasatinib—Abdominal pain—Irinotecan—colon cancer	0.00012	0.00102	CcSEcCtD
Dasatinib—Body temperature increased—Irinotecan—colon cancer	0.00012	0.00102	CcSEcCtD
Dasatinib—Feeling abnormal—Fluorouracil—colon cancer	0.00012	0.00102	CcSEcCtD
Dasatinib—Muscle spasms—Capecitabine—colon cancer	0.00012	0.00101	CcSEcCtD
Dasatinib—Pneumonia—Methotrexate—colon cancer	0.00012	0.00101	CcSEcCtD
Dasatinib—Infestation—Methotrexate—colon cancer	0.000119	0.00101	CcSEcCtD
Dasatinib—Infestation NOS—Methotrexate—colon cancer	0.000119	0.00101	CcSEcCtD
Dasatinib—CYP1A1—digestive system—colon cancer	0.000119	0.00101	CbGeAlD
Dasatinib—Vision blurred—Capecitabine—colon cancer	0.000118	0.000994	CcSEcCtD
Dasatinib—Tremor—Capecitabine—colon cancer	0.000117	0.000989	CcSEcCtD
Dasatinib—Renal failure—Methotrexate—colon cancer	0.000117	0.000988	CcSEcCtD
Dasatinib—CYP3A5—digestive system—colon cancer	0.000116	0.000988	CbGeAlD
Dasatinib—Stomatitis—Methotrexate—colon cancer	0.000116	0.00098	CcSEcCtD
Dasatinib—Ill-defined disorder—Capecitabine—colon cancer	0.000116	0.000979	CcSEcCtD
Dasatinib—Urticaria—Fluorouracil—colon cancer	0.000116	0.000979	CcSEcCtD
Dasatinib—Conjunctivitis—Methotrexate—colon cancer	0.000116	0.000977	CcSEcCtD
Dasatinib—Anaemia—Capecitabine—colon cancer	0.000115	0.000975	CcSEcCtD
Dasatinib—ABCG2—bone marrow—colon cancer	0.000115	0.000981	CbGeAlD
Dasatinib—Body temperature increased—Fluorouracil—colon cancer	0.000115	0.000974	CcSEcCtD
Dasatinib—Hypersensitivity—Vincristine—colon cancer	0.000115	0.000973	CcSEcCtD
Dasatinib—Haematuria—Methotrexate—colon cancer	0.000113	0.000958	CcSEcCtD
Dasatinib—ABL1—lymph node—colon cancer	0.000113	0.000964	CbGeAlD
Dasatinib—Malaise—Capecitabine—colon cancer	0.000113	0.000952	CcSEcCtD
Dasatinib—Hepatobiliary disease—Methotrexate—colon cancer	0.000112	0.000951	CcSEcCtD
Dasatinib—Epistaxis—Methotrexate—colon cancer	0.000112	0.000948	CcSEcCtD
Dasatinib—Vertigo—Capecitabine—colon cancer	0.000112	0.000948	CcSEcCtD
Dasatinib—Hypersensitivity—Irinotecan—colon cancer	0.000112	0.000948	CcSEcCtD
Dasatinib—Asthenia—Vincristine—colon cancer	0.000112	0.000948	CcSEcCtD
Dasatinib—Syncope—Capecitabine—colon cancer	0.000112	0.000946	CcSEcCtD
Dasatinib—ABCG2—vagina—colon cancer	0.00011	0.00094	CbGeAlD
Dasatinib—Palpitations—Capecitabine—colon cancer	0.00011	0.000932	CcSEcCtD
Dasatinib—Loss of consciousness—Capecitabine—colon cancer	0.00011	0.000927	CcSEcCtD
Dasatinib—Asthenia—Irinotecan—colon cancer	0.000109	0.000923	CcSEcCtD
Dasatinib—Cough—Capecitabine—colon cancer	0.000109	0.000921	CcSEcCtD
Dasatinib—Hypertension—Capecitabine—colon cancer	0.000108	0.000911	CcSEcCtD
Dasatinib—Hypersensitivity—Fluorouracil—colon cancer	0.000107	0.000908	CcSEcCtD
Dasatinib—Haemoglobin—Methotrexate—colon cancer	0.000107	0.000907	CcSEcCtD
Dasatinib—Diarrhoea—Vincristine—colon cancer	0.000107	0.000904	CcSEcCtD
Dasatinib—Hepatitis—Methotrexate—colon cancer	0.000107	0.000902	CcSEcCtD
Dasatinib—Haemorrhage—Methotrexate—colon cancer	0.000107	0.000902	CcSEcCtD
Dasatinib—Arthralgia—Capecitabine—colon cancer	0.000106	0.000898	CcSEcCtD
Dasatinib—Chest pain—Capecitabine—colon cancer	0.000106	0.000898	CcSEcCtD
Dasatinib—Myalgia—Capecitabine—colon cancer	0.000106	0.000898	CcSEcCtD
Dasatinib—CYP3A4—renal system—colon cancer	0.000106	0.000904	CbGeAlD
Dasatinib—Anxiety—Capecitabine—colon cancer	0.000106	0.000895	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000106	0.000892	CcSEcCtD
Dasatinib—Urinary tract disorder—Methotrexate—colon cancer	0.000105	0.000891	CcSEcCtD
Dasatinib—Discomfort—Capecitabine—colon cancer	0.000105	0.000888	CcSEcCtD
Dasatinib—CYP1A1—vagina—colon cancer	0.000105	0.000892	CbGeAlD
Dasatinib—Urethral disorder—Methotrexate—colon cancer	0.000105	0.000885	CcSEcCtD
Dasatinib—Diarrhoea—Irinotecan—colon cancer	0.000104	0.00088	CcSEcCtD
Dasatinib—Dizziness—Vincristine—colon cancer	0.000103	0.000874	CcSEcCtD
Dasatinib—Pruritus—Fluorouracil—colon cancer	0.000103	0.000872	CcSEcCtD
Dasatinib—Visual impairment—Methotrexate—colon cancer	0.000103	0.00087	CcSEcCtD
Dasatinib—Confusional state—Capecitabine—colon cancer	0.000103	0.000868	CcSEcCtD
Dasatinib—CYP3A5—vagina—colon cancer	0.000103	0.000872	CbGeAlD
Dasatinib—Oedema—Capecitabine—colon cancer	0.000102	0.000861	CcSEcCtD
Dasatinib—Infection—Capecitabine—colon cancer	0.000101	0.000856	CcSEcCtD
Dasatinib—Erythema multiforme—Methotrexate—colon cancer	0.000101	0.000853	CcSEcCtD
Dasatinib—Dizziness—Irinotecan—colon cancer	0.000101	0.000851	CcSEcCtD
Dasatinib—Shock—Capecitabine—colon cancer	0.0001	0.000847	CcSEcCtD
Dasatinib—Nervous system disorder—Capecitabine—colon cancer	9.99e-05	0.000845	CcSEcCtD
Dasatinib—Eye disorder—Methotrexate—colon cancer	9.98e-05	0.000843	CcSEcCtD
Dasatinib—Diarrhoea—Fluorouracil—colon cancer	9.98e-05	0.000843	CcSEcCtD
Dasatinib—Thrombocytopenia—Capecitabine—colon cancer	9.98e-05	0.000843	CcSEcCtD
Dasatinib—Tinnitus—Methotrexate—colon cancer	9.95e-05	0.000841	CcSEcCtD
Dasatinib—Tachycardia—Capecitabine—colon cancer	9.94e-05	0.000841	CcSEcCtD
Dasatinib—Vomiting—Vincristine—colon cancer	9.94e-05	0.00084	CcSEcCtD
Dasatinib—ABCB1—embryo—colon cancer	9.94e-05	0.000845	CbGeAlD
Dasatinib—Cardiac disorder—Methotrexate—colon cancer	9.91e-05	0.000837	CcSEcCtD
Dasatinib—Skin disorder—Capecitabine—colon cancer	9.9e-05	0.000836	CcSEcCtD
Dasatinib—Rash—Vincristine—colon cancer	9.86e-05	0.000833	CcSEcCtD
Dasatinib—Hyperhidrosis—Capecitabine—colon cancer	9.85e-05	0.000833	CcSEcCtD
Dasatinib—Dermatitis—Vincristine—colon cancer	9.85e-05	0.000832	CcSEcCtD
Dasatinib—Headache—Vincristine—colon cancer	9.79e-05	0.000828	CcSEcCtD
Dasatinib—Anorexia—Capecitabine—colon cancer	9.71e-05	0.000821	CcSEcCtD
Dasatinib—Angiopathy—Methotrexate—colon cancer	9.69e-05	0.000819	CcSEcCtD
Dasatinib—Vomiting—Irinotecan—colon cancer	9.68e-05	0.000818	CcSEcCtD
Dasatinib—Immune system disorder—Methotrexate—colon cancer	9.64e-05	0.000815	CcSEcCtD
Dasatinib—Dizziness—Fluorouracil—colon cancer	9.64e-05	0.000815	CcSEcCtD
Dasatinib—Mediastinal disorder—Methotrexate—colon cancer	9.62e-05	0.000813	CcSEcCtD
Dasatinib—Rash—Irinotecan—colon cancer	9.6e-05	0.000811	CcSEcCtD
Dasatinib—CYP1B1—lymph node—colon cancer	9.6e-05	0.000816	CbGeAlD
Dasatinib—Dermatitis—Irinotecan—colon cancer	9.59e-05	0.000811	CcSEcCtD
Dasatinib—Chills—Methotrexate—colon cancer	9.58e-05	0.00081	CcSEcCtD
Dasatinib—Headache—Irinotecan—colon cancer	9.54e-05	0.000806	CcSEcCtD
Dasatinib—Hypotension—Capecitabine—colon cancer	9.52e-05	0.000805	CcSEcCtD
Dasatinib—Alopecia—Methotrexate—colon cancer	9.43e-05	0.000797	CcSEcCtD
Dasatinib—Mental disorder—Methotrexate—colon cancer	9.35e-05	0.000791	CcSEcCtD
Dasatinib—ABCG2—liver—colon cancer	9.32e-05	0.000793	CbGeAlD
Dasatinib—Malnutrition—Methotrexate—colon cancer	9.29e-05	0.000786	CcSEcCtD
Dasatinib—Erythema—Methotrexate—colon cancer	9.29e-05	0.000786	CcSEcCtD
Dasatinib—Nausea—Vincristine—colon cancer	9.29e-05	0.000785	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Capecitabine—colon cancer	9.28e-05	0.000785	CcSEcCtD
Dasatinib—Vomiting—Fluorouracil—colon cancer	9.27e-05	0.000784	CcSEcCtD
Dasatinib—Insomnia—Capecitabine—colon cancer	9.22e-05	0.000779	CcSEcCtD
Dasatinib—Rash—Fluorouracil—colon cancer	9.19e-05	0.000777	CcSEcCtD
Dasatinib—Dermatitis—Fluorouracil—colon cancer	9.18e-05	0.000776	CcSEcCtD
Dasatinib—Headache—Fluorouracil—colon cancer	9.13e-05	0.000772	CcSEcCtD
Dasatinib—Dysgeusia—Methotrexate—colon cancer	9.1e-05	0.000769	CcSEcCtD
Dasatinib—Dyspnoea—Capecitabine—colon cancer	9.08e-05	0.000768	CcSEcCtD
Dasatinib—Nausea—Irinotecan—colon cancer	9.04e-05	0.000764	CcSEcCtD
Dasatinib—Dyspepsia—Capecitabine—colon cancer	8.97e-05	0.000758	CcSEcCtD
Dasatinib—CYP1A2—liver—colon cancer	8.97e-05	0.000763	CbGeAlD
Dasatinib—Decreased appetite—Capecitabine—colon cancer	8.86e-05	0.000749	CcSEcCtD
Dasatinib—CYP1A1—liver—colon cancer	8.85e-05	0.000753	CbGeAlD
Dasatinib—Gastrointestinal disorder—Capecitabine—colon cancer	8.8e-05	0.000743	CcSEcCtD
Dasatinib—Fatigue—Capecitabine—colon cancer	8.78e-05	0.000742	CcSEcCtD
Dasatinib—Vision blurred—Methotrexate—colon cancer	8.76e-05	0.00074	CcSEcCtD
Dasatinib—CYP3A4—digestive system—colon cancer	8.71e-05	0.000741	CbGeAlD
Dasatinib—Pain—Capecitabine—colon cancer	8.71e-05	0.000736	CcSEcCtD
Dasatinib—Constipation—Capecitabine—colon cancer	8.71e-05	0.000736	CcSEcCtD
Dasatinib—Nausea—Fluorouracil—colon cancer	8.66e-05	0.000732	CcSEcCtD
Dasatinib—CYP3A5—liver—colon cancer	8.65e-05	0.000736	CbGeAlD
Dasatinib—Ill-defined disorder—Methotrexate—colon cancer	8.62e-05	0.000729	CcSEcCtD
Dasatinib—Anaemia—Methotrexate—colon cancer	8.59e-05	0.000726	CcSEcCtD
Dasatinib—Feeling abnormal—Capecitabine—colon cancer	8.4e-05	0.00071	CcSEcCtD
Dasatinib—Malaise—Methotrexate—colon cancer	8.38e-05	0.000708	CcSEcCtD
Dasatinib—Vertigo—Methotrexate—colon cancer	8.35e-05	0.000706	CcSEcCtD
Dasatinib—Gastrointestinal pain—Capecitabine—colon cancer	8.33e-05	0.000704	CcSEcCtD
Dasatinib—Cough—Methotrexate—colon cancer	8.11e-05	0.000685	CcSEcCtD
Dasatinib—ABCB1—epithelium—colon cancer	8.11e-05	0.00069	CbGeAlD
Dasatinib—Urticaria—Capecitabine—colon cancer	8.09e-05	0.000684	CcSEcCtD
Dasatinib—Body temperature increased—Capecitabine—colon cancer	8.05e-05	0.000681	CcSEcCtD
Dasatinib—Abdominal pain—Capecitabine—colon cancer	8.05e-05	0.000681	CcSEcCtD
Dasatinib—Convulsion—Methotrexate—colon cancer	8.05e-05	0.000681	CcSEcCtD
Dasatinib—Arthralgia—Methotrexate—colon cancer	7.91e-05	0.000669	CcSEcCtD
Dasatinib—Chest pain—Methotrexate—colon cancer	7.91e-05	0.000669	CcSEcCtD
Dasatinib—Myalgia—Methotrexate—colon cancer	7.91e-05	0.000669	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	7.86e-05	0.000664	CcSEcCtD
Dasatinib—Discomfort—Methotrexate—colon cancer	7.82e-05	0.000661	CcSEcCtD
Dasatinib—Confusional state—Methotrexate—colon cancer	7.65e-05	0.000646	CcSEcCtD
Dasatinib—Infection—Methotrexate—colon cancer	7.54e-05	0.000637	CcSEcCtD
Dasatinib—ABCB1—renal system—colon cancer	7.52e-05	0.00064	CbGeAlD
Dasatinib—Hypersensitivity—Capecitabine—colon cancer	7.51e-05	0.000634	CcSEcCtD
Dasatinib—Nervous system disorder—Methotrexate—colon cancer	7.44e-05	0.000629	CcSEcCtD
Dasatinib—Thrombocytopenia—Methotrexate—colon cancer	7.43e-05	0.000628	CcSEcCtD
Dasatinib—Skin disorder—Methotrexate—colon cancer	7.37e-05	0.000623	CcSEcCtD
Dasatinib—Hyperhidrosis—Methotrexate—colon cancer	7.33e-05	0.00062	CcSEcCtD
Dasatinib—Asthenia—Capecitabine—colon cancer	7.31e-05	0.000618	CcSEcCtD
Dasatinib—Anorexia—Methotrexate—colon cancer	7.23e-05	0.000611	CcSEcCtD
Dasatinib—Pruritus—Capecitabine—colon cancer	7.21e-05	0.000609	CcSEcCtD
Dasatinib—ABCG2—lymph node—colon cancer	7.14e-05	0.000608	CbGeAlD
Dasatinib—Hypotension—Methotrexate—colon cancer	7.09e-05	0.000599	CcSEcCtD
Dasatinib—Diarrhoea—Capecitabine—colon cancer	6.97e-05	0.000589	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Methotrexate—colon cancer	6.91e-05	0.000584	CcSEcCtD
Dasatinib—Insomnia—Methotrexate—colon cancer	6.86e-05	0.00058	CcSEcCtD
Dasatinib—CYP1A1—lymph node—colon cancer	6.78e-05	0.000577	CbGeAlD
Dasatinib—Dyspnoea—Methotrexate—colon cancer	6.76e-05	0.000572	CcSEcCtD
Dasatinib—Somnolence—Methotrexate—colon cancer	6.74e-05	0.00057	CcSEcCtD
Dasatinib—Dizziness—Capecitabine—colon cancer	6.74e-05	0.000569	CcSEcCtD
Dasatinib—Dyspepsia—Methotrexate—colon cancer	6.68e-05	0.000564	CcSEcCtD
Dasatinib—Decreased appetite—Methotrexate—colon cancer	6.59e-05	0.000557	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Methotrexate—colon cancer	6.55e-05	0.000553	CcSEcCtD
Dasatinib—Fatigue—Methotrexate—colon cancer	6.54e-05	0.000553	CcSEcCtD
Dasatinib—CYP3A4—liver—colon cancer	6.49e-05	0.000552	CbGeAlD
Dasatinib—Pain—Methotrexate—colon cancer	6.49e-05	0.000548	CcSEcCtD
Dasatinib—Vomiting—Capecitabine—colon cancer	6.48e-05	0.000548	CcSEcCtD
Dasatinib—Rash—Capecitabine—colon cancer	6.42e-05	0.000543	CcSEcCtD
Dasatinib—Dermatitis—Capecitabine—colon cancer	6.42e-05	0.000542	CcSEcCtD
Dasatinib—Headache—Capecitabine—colon cancer	6.38e-05	0.00054	CcSEcCtD
Dasatinib—Feeling abnormal—Methotrexate—colon cancer	6.25e-05	0.000528	CcSEcCtD
Dasatinib—ABCB1—lymphoid tissue—colon cancer	6.24e-05	0.000531	CbGeAlD
Dasatinib—Gastrointestinal pain—Methotrexate—colon cancer	6.2e-05	0.000524	CcSEcCtD
Dasatinib—ABCB1—digestive system—colon cancer	6.17e-05	0.000525	CbGeAlD
Dasatinib—Nausea—Capecitabine—colon cancer	6.05e-05	0.000512	CcSEcCtD
Dasatinib—Urticaria—Methotrexate—colon cancer	6.03e-05	0.000509	CcSEcCtD
Dasatinib—Abdominal pain—Methotrexate—colon cancer	6e-05	0.000507	CcSEcCtD
Dasatinib—Body temperature increased—Methotrexate—colon cancer	6e-05	0.000507	CcSEcCtD
Dasatinib—ABCB1—bone marrow—colon cancer	5.69e-05	0.000484	CbGeAlD
Dasatinib—Hypersensitivity—Methotrexate—colon cancer	5.59e-05	0.000472	CcSEcCtD
Dasatinib—ABCB1—vagina—colon cancer	5.45e-05	0.000463	CbGeAlD
Dasatinib—Asthenia—Methotrexate—colon cancer	5.44e-05	0.00046	CcSEcCtD
Dasatinib—Pruritus—Methotrexate—colon cancer	5.37e-05	0.000454	CcSEcCtD
Dasatinib—Diarrhoea—Methotrexate—colon cancer	5.19e-05	0.000439	CcSEcCtD
Dasatinib—Dizziness—Methotrexate—colon cancer	5.02e-05	0.000424	CcSEcCtD
Dasatinib—Vomiting—Methotrexate—colon cancer	4.82e-05	0.000408	CcSEcCtD
Dasatinib—Rash—Methotrexate—colon cancer	4.78e-05	0.000404	CcSEcCtD
Dasatinib—Dermatitis—Methotrexate—colon cancer	4.78e-05	0.000404	CcSEcCtD
Dasatinib—Headache—Methotrexate—colon cancer	4.75e-05	0.000402	CcSEcCtD
Dasatinib—ABCB1—liver—colon cancer	4.6e-05	0.000391	CbGeAlD
Dasatinib—Nausea—Methotrexate—colon cancer	4.51e-05	0.000381	CcSEcCtD
Dasatinib—ABCB1—lymph node—colon cancer	3.52e-05	0.0003	CbGeAlD
Dasatinib—FYN—Disease—KRAS—colon cancer	2.02e-06	1.1e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—PIK3CA—colon cancer	2.02e-06	1.1e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—PIK3CA—colon cancer	2.01e-06	1.1e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—EP300—colon cancer	2.01e-06	1.09e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—NRAS—colon cancer	2e-06	1.09e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—AKT1—colon cancer	2e-06	1.09e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—AKT1—colon cancer	2e-06	1.09e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CASP3—colon cancer	2e-06	1.09e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CTNNB1—colon cancer	1.99e-06	1.09e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCND1—colon cancer	1.98e-06	1.08e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—HRAS—colon cancer	1.98e-06	1.08e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—TYMS—colon cancer	1.98e-06	1.08e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.98e-06	1.08e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—SRC—colon cancer	1.97e-06	1.07e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CTNNB1—colon cancer	1.97e-06	1.07e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CASP3—colon cancer	1.97e-06	1.07e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—NRAS—colon cancer	1.96e-06	1.07e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—colon cancer	1.96e-06	1.06e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CDKN1A—colon cancer	1.95e-06	1.06e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCND1—colon cancer	1.94e-06	1.06e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—HRAS—colon cancer	1.94e-06	1.06e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—PIK3CA—colon cancer	1.94e-06	1.06e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—HRAS—colon cancer	1.94e-06	1.06e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—HRAS—colon cancer	1.93e-06	1.05e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—colon cancer	1.93e-06	1.05e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—BRAF—colon cancer	1.93e-06	1.05e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KRAS—colon cancer	1.93e-06	1.05e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PIK3CA—colon cancer	1.93e-06	1.05e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—KRAS—colon cancer	1.92e-06	1.05e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CTNNB1—colon cancer	1.92e-06	1.05e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—colon cancer	1.92e-06	1.05e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CDKN1A—colon cancer	1.92e-06	1.05e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—PIK3CA—colon cancer	1.91e-06	1.04e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCND1—colon cancer	1.91e-06	1.04e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.91e-06	1.04e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NRAS—colon cancer	1.9e-06	1.03e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—AKT1—colon cancer	1.9e-06	1.03e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CTNNB1—colon cancer	1.89e-06	1.03e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—colon cancer	1.89e-06	1.03e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CASP3—colon cancer	1.89e-06	1.03e-05	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—AKT1—colon cancer	1.89e-06	1.03e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—colon cancer	1.88e-06	1.03e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CDKN1A—colon cancer	1.88e-06	1.02e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—NRAS—colon cancer	1.88e-06	1.02e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—AKT1—colon cancer	1.87e-06	1.02e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—colon cancer	1.87e-06	1.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CASP3—colon cancer	1.87e-06	1.02e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—EP300—colon cancer	1.87e-06	1.02e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MYC—colon cancer	1.87e-06	1.02e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—colon cancer	1.86e-06	1.02e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TGFB1—colon cancer	1.86e-06	1.01e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—PIK3CA—colon cancer	1.86e-06	1.01e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PPARG—colon cancer	1.86e-06	1.01e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—EP300—colon cancer	1.85e-06	1.01e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CDKN1A—colon cancer	1.85e-06	1.01e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—AKT1—colon cancer	1.85e-06	1.01e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—colon cancer	1.84e-06	1e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EP300—colon cancer	1.83e-06	9.95e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—colon cancer	1.83e-06	9.94e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—KRAS—colon cancer	1.83e-06	9.94e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—colon cancer	1.82e-06	9.93e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CTNNB1—colon cancer	1.82e-06	9.93e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—TGFB1—colon cancer	1.82e-06	9.91e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—colon cancer	1.82e-06	9.9e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CTNNB1—colon cancer	1.8e-06	9.81e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—colon cancer	1.79e-06	9.77e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EP300—colon cancer	1.79e-06	9.74e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—colon cancer	1.79e-06	9.72e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—colon cancer	1.78e-06	9.72e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CDKN1A—colon cancer	1.78e-06	9.7e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—SRC—colon cancer	1.78e-06	9.67e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PIK3CA—colon cancer	1.77e-06	9.66e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—colon cancer	1.77e-06	9.65e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—PIK3CA—colon cancer	1.77e-06	9.63e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—colon cancer	1.77e-06	9.62e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TGFB1—colon cancer	1.76e-06	9.6e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EP300—colon cancer	1.76e-06	9.59e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CDKN1A—colon cancer	1.76e-06	9.58e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PPARG—colon cancer	1.76e-06	9.57e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—colon cancer	1.75e-06	9.53e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—SRC—colon cancer	1.74e-06	9.47e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—NRAS—colon cancer	1.73e-06	9.44e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—colon cancer	1.73e-06	9.42e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—colon cancer	1.73e-06	9.41e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—colon cancer	1.72e-06	9.39e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—colon cancer	1.72e-06	9.37e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—colon cancer	1.72e-06	9.35e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—colon cancer	1.71e-06	9.33e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SRC—colon cancer	1.71e-06	9.32e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—colon cancer	1.71e-06	9.32e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—colon cancer	1.71e-06	9.32e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NRAS—colon cancer	1.71e-06	9.31e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—colon cancer	1.71e-06	9.3e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—EP300—colon cancer	1.7e-06	9.25e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EP300—colon cancer	1.7e-06	9.23e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—colon cancer	1.69e-06	9.22e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—colon cancer	1.69e-06	9.18e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—colon cancer	1.68e-06	9.13e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EP300—colon cancer	1.67e-06	9.12e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NRAS—colon cancer	1.67e-06	9.11e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—colon cancer	1.67e-06	9.1e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—colon cancer	1.67e-06	9.08e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—colon cancer	1.66e-06	9.06e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—colon cancer	1.65e-06	8.99e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SRC—colon cancer	1.65e-06	8.98e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NRAS—colon cancer	1.65e-06	8.97e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.65e-06	8.96e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—colon cancer	1.65e-06	8.96e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—colon cancer	1.64e-06	8.94e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—colon cancer	1.64e-06	8.91e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—colon cancer	1.64e-06	8.91e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—colon cancer	1.63e-06	8.89e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SRC—colon cancer	1.63e-06	8.86e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—colon cancer	1.62e-06	8.8e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—colon cancer	1.61e-06	8.79e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFB1—colon cancer	1.61e-06	8.77e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ABCB1—colon cancer	1.61e-06	8.77e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—colon cancer	1.61e-06	8.75e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—colon cancer	1.59e-06	8.67e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—colon cancer	1.59e-06	8.67e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFB1—colon cancer	1.59e-06	8.65e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NRAS—colon cancer	1.59e-06	8.64e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—colon cancer	1.59e-06	8.63e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—colon cancer	1.58e-06	8.63e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—colon cancer	1.58e-06	8.63e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TYMS—colon cancer	1.58e-06	8.61e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—colon cancer	1.58e-06	8.6e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CTNNB1—colon cancer	1.58e-06	8.59e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—colon cancer	1.58e-06	8.58e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—colon cancer	1.58e-06	8.58e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NRAS—colon cancer	1.57e-06	8.53e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—colon cancer	1.56e-06	8.52e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—colon cancer	1.56e-06	8.49e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—colon cancer	1.56e-06	8.48e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFB1—colon cancer	1.55e-06	8.47e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—colon cancer	1.55e-06	8.45e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—colon cancer	1.55e-06	8.43e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1A—colon cancer	1.54e-06	8.39e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—colon cancer	1.53e-06	8.36e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—colon cancer	1.53e-06	8.35e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFB1—colon cancer	1.53e-06	8.34e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—colon cancer	1.52e-06	8.3e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—colon cancer	1.52e-06	8.28e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—colon cancer	1.5e-06	8.17e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—colon cancer	1.5e-06	8.17e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—colon cancer	1.49e-06	8.13e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—colon cancer	1.48e-06	8.09e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—colon cancer	1.48e-06	8.05e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFB1—colon cancer	1.47e-06	8.03e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—colon cancer	1.47e-06	8.01e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—colon cancer	1.47e-06	7.98e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EP300—colon cancer	1.47e-06	7.98e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—colon cancer	1.46e-06	7.97e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—colon cancer	1.46e-06	7.94e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFB1—colon cancer	1.45e-06	7.92e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—colon cancer	1.45e-06	7.9e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—colon cancer	1.45e-06	7.89e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—colon cancer	1.45e-06	7.89e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—colon cancer	1.44e-06	7.87e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—colon cancer	1.44e-06	7.87e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—colon cancer	1.44e-06	7.84e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—colon cancer	1.43e-06	7.8e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—colon cancer	1.43e-06	7.77e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SRC—colon cancer	1.43e-06	7.76e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—colon cancer	1.42e-06	7.72e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—colon cancer	1.41e-06	7.68e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARG—colon cancer	1.4e-06	7.64e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CTNNB1—colon cancer	1.4e-06	7.6e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—colon cancer	1.39e-06	7.56e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—colon cancer	1.39e-06	7.56e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—colon cancer	1.38e-06	7.53e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—colon cancer	1.38e-06	7.52e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—colon cancer	1.37e-06	7.48e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRAS—colon cancer	1.37e-06	7.47e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—colon cancer	1.37e-06	7.47e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—colon cancer	1.37e-06	7.46e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—colon cancer	1.37e-06	7.43e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1A—colon cancer	1.36e-06	7.43e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—colon cancer	1.35e-06	7.36e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—colon cancer	1.35e-06	7.34e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—colon cancer	1.32e-06	7.21e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—colon cancer	1.31e-06	7.12e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—colon cancer	1.3e-06	7.09e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EP300—colon cancer	1.3e-06	7.07e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—colon cancer	1.29e-06	7.05e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—colon cancer	1.28e-06	6.97e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—colon cancer	1.28e-06	6.96e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFB1—colon cancer	1.27e-06	6.94e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—colon cancer	1.27e-06	6.91e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—colon cancer	1.26e-06	6.89e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—colon cancer	1.26e-06	6.86e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—colon cancer	1.26e-06	6.84e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—colon cancer	1.25e-06	6.83e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—colon cancer	1.25e-06	6.81e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—colon cancer	1.25e-06	6.8e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ABCB1—colon cancer	1.24e-06	6.77e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—colon cancer	1.24e-06	6.74e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—colon cancer	1.23e-06	6.69e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—colon cancer	1.23e-06	6.67e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—colon cancer	1.22e-06	6.67e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TYMS—colon cancer	1.22e-06	6.65e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.22e-06	6.63e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—EP300—colon cancer	1.22e-06	6.63e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRAS—colon cancer	1.21e-06	6.61e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—colon cancer	1.21e-06	6.61e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—colon cancer	1.21e-06	6.61e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—colon cancer	1.2e-06	6.56e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—colon cancer	1.2e-06	6.52e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—colon cancer	1.18e-06	6.43e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—colon cancer	1.16e-06	6.32e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—EP300—colon cancer	1.15e-06	6.26e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—colon cancer	1.15e-06	6.24e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—colon cancer	1.13e-06	6.16e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFB1—colon cancer	1.13e-06	6.14e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—colon cancer	1.13e-06	6.14e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARG—colon cancer	1.12e-06	6.1e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—colon cancer	1.12e-06	6.1e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—colon cancer	1.11e-06	6.02e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—colon cancer	1.1e-06	6.01e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—colon cancer	1.1e-06	6.01e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—colon cancer	1.08e-06	5.91e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—colon cancer	1.08e-06	5.89e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—colon cancer	1.06e-06	5.79e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—colon cancer	1.05e-06	5.71e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—colon cancer	1.04e-06	5.69e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—colon cancer	1.03e-06	5.59e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—colon cancer	1.02e-06	5.58e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—colon cancer	1.01e-06	5.51e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—colon cancer	1e-06	5.46e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—colon cancer	9.6e-07	5.23e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—colon cancer	9.29e-07	5.06e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—EP300—colon cancer	9.18e-07	5e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—colon cancer	9e-07	4.9e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—colon cancer	8.88e-07	4.84e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—colon cancer	8.86e-07	4.82e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—colon cancer	8.81e-07	4.8e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARG—colon cancer	8.65e-07	4.71e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—colon cancer	8.5e-07	4.63e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—colon cancer	7.84e-07	4.27e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—colon cancer	7.35e-07	4e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—EP300—colon cancer	7.33e-07	3.99e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—colon cancer	6.95e-07	3.78e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—colon cancer	6.8e-07	3.7e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—colon cancer	6.79e-07	3.7e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—EP300—colon cancer	5.66e-07	3.08e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—colon cancer	5.55e-07	3.02e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—colon cancer	5.42e-07	2.95e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—colon cancer	4.43e-07	2.41e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—colon cancer	4.18e-07	2.28e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—colon cancer	3.42e-07	1.86e-06	CbGpPWpGaD
